Pregabalin effects on neural response to emotional faces

Frontiers in Human Neuroscience

Volumn 6, Issue MAR, 2012, Pages

  Aupperle, Robin L ^a,c,e   Tankersley, Dharol ^a,f,g   Ravindran, Lakshmi N ^d   Flagan, Taru ^a   Stein, Nathan R ^a   Stein, Murray B ^a,b,c   Paulus, Martin P ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g Schipul Technologies   (United States)

Author keywords

Anxiety; Anxiolytic; Benzodiazepine; Emotion; Fmri; Pharmaco imaging; Pregabalin

Indexed keywords

PLACEBO; PREGABALIN;

ADULT; AMYGDALOID NUCLEUS; ANGER; ANTERIOR CINGULATE; ARTICLE; CONDITIONED EMOTIONAL RESPONSE TEST; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; EMOTION; EVENT RELATED POTENTIAL; FACIAL EXPRESSION; FEAR; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INFORMATION PROCESSING; INSULA; MALE; NERVE CONDUCTION; NERVE POTENTIAL; NORMAL HUMAN; PREFRONTAL CORTEX; RANDOMIZED CONTROLLED TRIAL; STIMULUS RESPONSE; TASK PERFORMANCE;

EID: 84876727579     PISSN: None     EISSN: 16625161     Source Type: Journal    
DOI: 10.3389/fnhum.2012.00042     Document Type: Article

References (78)

1. Adolphs, R. (2008). Fear, faces, and the human amygdala. Curr. Opin. Neurobiol. 18, 166-172.
2. Akerstedt, T., and Gillberg, M. (1990). Subjective and objective sleepiness in the active individual. Int. J. Neurosci. 52, 29-37.
3. Anderson, I. M., Del-Ben, C. M., McKie, S., Richardson, P., Williams, S. R., Elliott, R., and Deakin, J. F. (2007). Citalopram modulation of neuronal responses to aversive face emotions: a functional MRI study. Neuroreport 18, 1351-1355.
4. Arce, E., Miller, D. A., Feinstein, J. S., Stein, M. B., and Paulus, M. P. (2006). Lorazepam dose-dependently decreases risk-taking related activation in limbic areas. Psychopharmacology (Berl.) 189, 105-116.
5. Arce, E., Simmons, A. N., Lovero, K. L., Stein, M. B., and Paulus, M. P. (2008). Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology (Berl.) 196, 661-672.
6. Atack, J. R. (2003). Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. Curr. Drug Targets CNS Neurol. Disord. 2, 213-232.
7. Aupperle, R. L., and Paulus, M. P. (2010). Neural systems underlying approach and avoidance in anxiety disorders. Dialogues Clin. Neurosci. 12, 305-319.
8. Aupperle, R. L., Ravindran, L., Tankersley, D., Flagan, T., Stein, N. R., Simmons, A. N., Stein, M. B., and Paulus, M. P. (2011). Pregabalin influences insula and amygdala activation during anticipation of emotional images. Neuro-psychopharmacology 36, 1466-1477.
9. Baldwin, D. S. (2008). Room for improvement in the pharmacological treatment of anxiety disorders. Curr. Pharm. Des. 14, 3482-3491.
10. Bereza, B. G., Machado, M., and Einarson, T. R. (2009). Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. Clin. Ther. 31, 1279-1308.
11. Botvinick, M. M. (2007). Conflict monitoring and decision making: reconciling two perspectives on anterior cingulate function. Cogn. Affect. Behav. Neurosci. 7, 356-366.
12. Brawek, B., Loffler, M., Dooley, D. J., Weyerbrock, A., and Feuerstein, T. J. (2008). Differential modulation of K(+)-evoked (3)H-neurotransmitter release from human neocortex by gabapentin and pregabalin. Naunyn Schmiedebergs Arch. Pharmacol. 376, 301-307.
13. Cannistraro, P. A., and Rauch, S. L. (2003). Neural circuitry of anxiety: evidence from structural and functional neuroimaging studies. Psychopharmacol. Bull. 37, 8-25.
14. Cloos, J. M., and Ferreira, V. (2009). Current use of benzodiazepines in anxiety disorders. Curr. Opin. Psychiatry 22, 90-95.
15. Cox, R. W. (1996). AFNI: software for analysis and visualization of functional magnetic resonance neu-roimages. Comput. Biomed. Res. 29, 162-173.
16. Craig, A. D. (2009). How do you feel-now? The anterior insula and human awareness. Nat. Rev. Neurosci. 10, 59-70.
17. Craig, A. D. (2011). Significance of the insula for the evolution of human awareness of feelings from the body. Ann. N.Y. Acad. Sci. 1225, 72-82.
18. Critchley, H. D., Wiens, S., Rotshtein, P., Ohman, A., and Dolan, R. J. (2004). Neural systems supporting interoceptive awareness. Nat. Neurosci. 7, 189-195.
19. Davis, M., and Whalen, P. J. (2001). The amygdala: vigilance and emotion. Mol. Psychiatry 6, 13-34.
20. Del-Ben, C. M., Deakin, J. F., McKie, S., Delvai, N. A., Williams, S. R., Elliott, R., Dolan, M., and Anderson, I. M. (2005). The effect of citalo-pram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an fMRI study. Neuropsychopharmacology 30, 1724-1734.
21. Dooley, D. J., Taylor, C. P., Donevan, S., and Feltner, D. (2007). Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol. Sci. 28, 75-82.
22. Ebner, K., and Singewald, N. (2006). The role of substance P in stress and anxiety responses. Amino Acids 31, 251-272.
23. Etkin, A., Egner, T., and Kalisch, R. (2011). Emotional processing in anterior cingulate and medial pre-frontal cortex. Trends Cogn. Sci. (Regul. Ed.) 15, 85-93.
24. Etkin, A., and Wager, T. D. (2007). Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am. J. Psychiatry 164, 1476-1488.
25. Feltner, D. E., Crockatt, J. G., Dubovsky, S. J., Cohn, C. K., Shrivastava, R. K., Targum, S. D., Liu-Dumaw, M., Carter, C. M., and Pande, A. C. (2003). A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J. Clin. Psychopharmacol. 23, 240-249.
26. Fink, K., Dooley, D. J., Meder, W. P., Suman-Chauhan, N., Duffy, S., Clusmann, H., and Gothert, M. (2002). Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42, 229-236.
27. Floyd, T. F., Ratcliffe, S. J., Wang, J., Resch, B., and Detre, J. A. (2003). Precision of the CASL-perfusion MRI technique for the measurement of cerebral blood flow in whole brain and vascular territories. J. Magn. Reson. Imaging 18, 649-655.
28. Fusar-Poli, P., Placentino, A., Carletti, F., Landi, P., Allen, P., Surguladze, S., Benedetti, F., Abbamonte, M., Gasparotti, R., Barale, F., Perez, J., Mcguire, P., and Politi, P. (2009). Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies. J. Psychiatry Neurosci. 34, 418-432.
29. Gordon, J. A., and Hen, R. (2004). The serotonergic system and anxiety. Neuromolecular Med. 5, 27-40.
30. Hariri, A. R., Tessitore, A., Mattay, V. S., Fera, F., and Weinberger, D. R. (2002). The amygdala response to emotional stimuli: a comparison of faces and scenes. Neuroimage 17, 317-323.
31. Hariri, A. R., and Whalen, P. J. (2011). The amygdala: inside and out. F1000 Biol. Rep. 3, 2.
32. Harmer, C. J., Mackay, C. E., Reid, C. B., Cowen, P. J., and Goodwin, G. M. (2006). Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol. Psychiatry 59, 816-820.
33. Hindmarch, I., Trick, L., and Ridout, F. (2005). A double-blind, placebo-and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl.) 183, 133-143.
34. Hoffman, D. L., Dukes, E. M., and Wittchen, H. U. (2008). Human and economic burden of generalized anxiety disorder. Depress. Anxiety 25, 72-90.
35. Hofmann, S. G., Ellard, K. K., and Siegle, G. J. (2011). Neurobiological correlates of cognitions in fear and anxiety: a cognitive-neurobiological information-processing model. Cogn. Emot. 26, 282-299.
36. Johnston, K., Westerfield, W., Momin, S., Phillippi, R., and Naidoo, A. (2009). The direct and indirect costs of employee depression, anxiety, and emotional disorders-an employer case study. J. Occup. Environ. Med. 51, 564-577.
37. Kalk, N. J., Nutt, D. J., and Lingford-Hughes, A. R. (2011). The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies. J. Psychopharmacol. 25, 3-16.
38. Kanske, P., Heissler, J., Schonfelder, S., Bongers, A., and Wessa, M. (2010). How to regulate emotion? Neural networks for reappraisal and distraction. Cereb. Cortex. 21, 1379-1388.
39. Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R., and Walters, E. E. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 617-627.
40. Kim, M. J., Loucks, R. A., Palmer, A. L., Brown, A. C., Solomon, K. M., Marchante, A. N., and Whalen, P. J. (2011). The structural and functional connectivity of the amygdala: from normal emotion to pathological anxiety. Behav. Brain Res. 223, 403-410.
41. Knutson, B., and Greer, S. M. (2008). Anticipatory affect: neural correlates and consequences for choice. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363, 3771-3786.
42. Lancaster, J. L., Woldorff, M. G., Parsons, L. M., Liotti, M., Freitas, C. S., Rainey, L., Kochunov, P. V., Nickerson, D., Mikiten, S. A., and Fox, P. T. (2000). Automated Talairach atlas labels for functional brain mapping. Hum. Brain Mapp. 10, 120-131.
43. Lowry, C. A., Johnson, P. L., Hay-Schmidt, A., Mikkelsen, J., and Shekhar, A. (2005). Modulation of anxiety circuits by serotonergic systems. Stress 8, 233-246.
44. Lydiard, R. B. (2003). The role of GABA in anxiety disorders. J. Clin. Psychiatry 64(Suppl. 3), 21-27.
45. Lydiard, R. B., Rickels, K., Herman, B., and Feltner, D. E. (2010). Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int. J. Neuropsychopharmacol. 13, 229-241.
46. Matsumoto, A., and Ekman, A.M., (1988). Japanese and Caucasian Facial Expressions of Emotion (IACFEE) [Slides]. San Francisco: Intercultural and Emotion Research Laboratory, Department of Psychology, San Francisco State University.
47. McIntosh, A., Cohen, A., Turnbull, N., Esmonde, L., Dennis, P., Eatock, J., Feetam, C., Hague, J., Hughes, I., Kelly, J., Kosky, N., Lear, G., Owens, L., Ratcliffe, J., and Salkovskis, P. (2004). Clinical Guidelines and Evidence Review for Panic Disorder and Generalised Anxiety Disorder. Sheffield: University of Sheffield/London: National Collaborating Center for Primary Care.
48. McKie, S., Del-Ben, C., Elliott, R., Williams, S., Del Vai, N., Anderson, I., and Deakin, J. F. (2005). Neu-ronal effects of acute citalopram detected by pharmacoMRI. Psycho-pharmacology (Berl.) 180, 680-686.
49. Millan, M. J. (2003). The neurobiology and control of anxious states. Prog. Neurobiol. 70, 83-244.
50. Montgomery, S. A., Tobias, K., Zornberg, G. L., Kasper, S., and Pande, A. C. (2006). Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J. Clin. Psychiatry 67, 771-782.
51. Morrison, S. E., and Salzman, C. D. (2010). Re-valuing the amygdala. Curr. Opin. Neurobiol. 20, 221-230.
52. Nutt, D., Mandel, F., and Baldinetti, F. (2008). Early onset anxiolytic efficacy after a single dose of pre-gabalin: double-blind, placebo-and active-comparator controlled evaluation using a dental anxiety model. J. Psychopharmacol. 23, 867-873.
53. Ochsner, K. N., and Gross, J. J. (2005). The cognitive control of emotion. Tre nd s Cog n. S ci. 9, 242-249.
54. Oulis, P., Konstantakopoulos, G., Kouzoupis, A. V., Masdrakis, V. G., Karakatsanis, N. A., Karapoulios, E., Kontoangelos, K. A., and Papadimitriou, G. N. (2008). Pregabalin in the discontinuation of long-term benzodiazepines' use. Hum. Psychopharmacol. 23, 337-340.
55. Pande, A. C., Crockatt, J. G., Feltner, D. E., Janney, C. A., Smith, W. T., Weisler, R., Londborg, P. D., Bielski, R. J., Zimbroff, D. L., Davidson, J. R., and Liu-Dumaw, M. (2003). Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am. J. Psychiatry 160, 533-540.
56. Pande, A. C., Feltner, D. E., Jefferson, J. W., Davidson, J. R., Pollack, M., Stein, M. B., Lydiard, R. B., Futterer, R., Robinson, P., Slomkowski, M., Duboff, E., Phelps, M., Janney, C. A., and Werth, J. L. (2004). Efficacy of the novel anxiolytic pre-gabalin in social anxiety disorder: a placebo-controlled, multicenter study. J. Clin. Psychopharmacol. 24, 141-149.
57. Paulus, M. P., Feinstein, J. S., Castillo, G., Simmons, A. N., and Stein, M. B. (2005). Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch. Gen. Psychiatry 62, 282-288.
58. Paulus, M. P., and Stein, M. B. (2006). An insular view of anxiety. Biol. Psychiatry 60, 383-387.
59. Paulus, M. P., and Stein, M. B. (2007). Role of functional magnetic resonance imaging in drug discovery. Neuropsychol. Rev. 17, 179-188.
60. Pirkola, S., Saarni, S., Suvisaari, J., Elovainio, M., Partonen, T., Aalto, A. M., Honkonen, T., Perala, J., and Lonnqvist, J. (2009). General health and quality-of-life measures in active, recent, and comorbid mental disorders: a population-based health 2000 study. Compr. Psychiatry 50, 108-114.
61. Pohl, R. B., Feltner, D. E., Fieve, R. R., and Pande, A. C. (2005). Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J. Clin. Psychopharmacol. 25, 151-158.
62. Rack-Gomer, A. L., Liau, J., and Liu, T. T. (2009). Caffeine reduces resting-state BOLD functional connectivity in the motor cortex. Neuroimage 46, 56-63.
63. Ravindran, L. N., and Stein, M. B. (2010). The pharmacologic treatment of anxiety disorders: a review of progress. J. Clin. Psychiatry 71, 839-854.
64. Rickels, K., Pollack, M. H., Feltner, D. E., Lydiard, R. B., Zimbroff, D. L., Bielski, R. J., Tobias, K., Brock, J. D., Zornberg, G. L., and Pande, A. C. (2005). Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of prega-balin and alprazolam. Arch. Gen. Psychiatry 62, 1022-1030.
65. Shin, L. M., and Liberzon, I. (2010). The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 35, 169-191.
66. Shin, L. M., Wright, C. I., Cannistraro, P. A., Wedig, M. M., Mcmullin, K., Martis, B., Macklin, M. L., Lasko, N. B., Cavanagh, S. R., Krangel, T. S., Orr, S. P., Pitman, R. K., Whalen, P. J., and Rauch, S. L. (2005). A functional magnetic resonance imaging study of amygdala and medial prefrontal cortex responses to overtly presented fearful faces in posttraumatic stress disorder. Arch. Gen. Psychiatry 62, 273-281.
67. Simmons, A. N., Arce, E., Lovero, K. L., Stein, M. B., and Paulus, M. P. (2009). Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. Int. J. Neuropsychopharmacol. 12, 1009-1020.
68. Spielberger, C. D., Gorsuch, R. L., Lushene, P. R., Vagg, P. R., and Jacobs, A. G. (1983). Manual for the State-Trait Anxiety Inventory (Form Y). Palo Alto: Consulting Psychologists Press, Inc.
69. Staugaard, S. R. (2010). Threatening faces and social anxiety: a literature review. Clin. Psychol. Rev. 30, 669-690.
70. Stein, M. B., Goldin, P. R., Sareen, J., Zorrilla, L. T., and Brown, G. G. (2002). Increased amygdala activation to angry and contemptuous faces in generalized social phobia. Arch. Gen. Psychiatry 59, 1027-1034.
71. Stein, M. B., Simmons, A. N., Feinstein, J. S., and Paulus, M. P. (2007). Increased amygdala and insula activation during emotion processing in anxiety-prone subjects. Am. J. Psychiatry 164, 318-327.
72. Takahashi, H., Yahata, N., Koeda, M., Takano, A., Asai, K., Suhara, T., and Okubo, Y. (2005). Effects of dopaminergic and serotoner-gic manipulation on emotional processing: a pharmacological fMRI study. Neuroimage 27, 991-1001.
73. Tassone, D. M., Boyce, E., Guyer, J., and Nuzum, D. (2007). Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin. Ther. 29, 26-48.
74. Tottenham, N., Tanaka, J. W., Leon, A. C., Mccarry, T., Nurse, M., Hare, T. A., Marcus, D. J., Westerlund, A., Casey, B. J., and Nelson, C. (2009). The NimStim set of facial expressions: judgments from untrained research participants. Psychiatry Res. 168, 242-249.
75. Vaswani, M., Linda, F. K., and Ramesh, S. (2003). Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 85-102.
76. Windischberger, C., Lanzenberger, R., Holik, A., Spindelegger, C., Stein, P., Moser, U., Gerstl, F., Fink, M., Moser, E., and Kasper, S. (2010). Area-specific modulation of neural activation comparing esci-talopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. Neuroimage 49, 1161-1170.
77. Wise, R. G., Lujan, B. J., Schweinhardt, P., Peskett, G. D., Rogers, R., and Tracey, I. (2007). The anxiolytic effects of midazolam during anticipation to pain revealed using fMRI. Magn. Reson. Imaging 25, 801-810.
78. Wong, E. C., Buxton, R. B., and Frank, L. R. (1998). A theoretical and experimental comparison of continuous and pulsed arterial spin labeling techniques for quantitative perfusion imaging. Magn. Reson. Med. 40, 348-355.